Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 161Neoplasm Metastasis 22Neoplasms 20Advanced Breast Cancer 13Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Hereditary Sensory and Autonomic Neuropathies 9Endometrial Neoplasms 8Triple Negative Breast Neoplasms 7Colorectal Neoplasms 6Uterine Cervical Neoplasms 5Squamous Cell Carcinoma of Head and Neck 5Prostatic Neoplasms 5Recurrence 4Neoplasms by Site 4Multiple Endocrine Neoplasia Type 1 4Breast Diseases 4Small Cell Lung Carcinoma 3Head and Neck Neoplasms 3Carcinoma, Ovarian Epithelial 3Uterine Neoplasms 2Stomach Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Locally Advanced (Inoperable) or Metastatic Breast Cancer 2Liposarcoma 2HER2-positive Metastatic Breast Cancer 2Advanced Solid Tumors 2Advanced Solid Tumor 2Urologic Neoplasms 1

Interventions

capivasertib 2Fulvestrant 2ribociclib 1palbociclib 1abemaciclib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Locally Advanced (Inoperable) or Metastatic Breast Cancer × Fulvestrant × Clear all
NCT04862663 2026-05-27

CAPItello-292

AstraZeneca

Phase 3 Recruiting
895 enrolled
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT04305496 2026-04-30

CAPItello-291

AstraZeneca

Phase 3 Active not recruiting
818 enrolled 19 charts 2 FDA
Breast

Locally Advanced (Inoperable) or Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡